Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Fed Meeting, U.S. Jobs in Focus for This Week Baystreet - Mon Jul 7, 8:15AM CDT

Tuesday U.S. Economic Lookahead NFIB optimism index (June) Consumer credit (May) ...

AZZ : 106.27 (-0.48%)
SAR : 24.90 (+0.48%)
CAG : 19.00 (-1.96%)
MTY.TO : 40.20 (-1.08%)
UNTY : 51.87 (-1.48%)
LEXX : 0.8145 (-2.35%)
PENG : 24.84 (+0.57%)
DAL : 55.71 (-4.13%)
BSET : 18.63 (-0.45%)
LEVI : 21.30 (-0.33%)
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock ACCESS Newswire - Mon Apr 28, 11:15AM CDT

KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing...

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)
Lexaria Announces $2 Million Registered Direct Offering of Common Stock ACCESS Newswire - Fri Apr 25, 3:00AM CDT

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology ACCESS Newswire - Wed Apr 23, 4:10AM CDT

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)
Lexaria Updates its Ongoing Human Study GLP-1-H24-4 ACCESS Newswire - Thu Apr 3, 4:10AM CDT

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)
Lexaria's Human GLP-1 Study #5 Begins Dosing ACCESS Newswire - Wed Apr 2, 4:05AM CDT

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R) ACCESS Newswire - Tue Mar 18, 4:15AM CDT

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience ACCESS Newswire - Thu Feb 27, 2:00AM CST

Lexaria executing a triple-pronged strategy in obesity and diabetes

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm ACCESS Newswire - Mon Feb 24, 2:00AM CST

5th study arm in 12-week Phase 1b Study receives lead clinical site approval

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide ACCESS Newswire - Thu Feb 20, 2:00AM CST

Pursuing the world's first-ever orally-dosed liraglutide

LEXXW : 0.1647 (+21.82%)
LEXX : 0.8145 (-2.35%)

Barchart Exclusives

Retirement Ready: 3 Dividend Stocks to Set and Forget Barchart - Tue Jul 15, 6:30PM CDT
These are three rock-solid dividend stocks you can buy now and confidently forget, knowing they’ll keep working for you year after year. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot